Biocept, Inc., a privately-held CLIA-certified laboratory testing company, and Clarient, Inc. (a GE Healthcare Company) say that they will be collaborating on the commercialization of a proprietary blood test for circulating tumor cells…
September 15, 2011 Proactive Investors One2One Investor Forum
The directors of ImmunoCellular Therapeutics (OTCBB: IMUC), International Stem Cell (OTCBB: ISCO) and OncoSec Medical Incorporated (OTCBB: ONCS) will be presenting.
ThermoGenesis Sees Explosive Growth Opportunities in Stem Cells
Mel Engle, CEO of ThermoGenesis [NASDAQ: KOOL] recently discussed with OneMedRadio, the company’s stem cell products and FDA approval that may have groundbreaking implications for the stem cell market.
InVivo Therapeutics Treats the Spinal Cord Itself, A Novel Technology
Frank Reynolds, President and CEO of InVivo Therapeutics describes the company’s strategy in bringing its unique spinal cord injury (SPI) products to market.
Arun Menawat Discusses Novadaq Technologies, a Surgical Imaging Company
Novadaq Technologies (TSX:NDQ) President & CEO Arun Menawat, Ph.D was interviewed by OneMedRadio and discusses the roll out of his surgical imaging technology.
E-Therapeutics expects to generate a “wealth of data” from clinical trials
E-Therapeutics (LON:ETX) expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates.
Inovio yields long-term immune responses from cervical cancer vaccine
Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
